{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:02:20Z","timestamp":1745294540265,"version":"3.40.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.fjurol.2024.102843","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:58:38Z","timestamp":1733533118000},"page":"102843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCG MEDAC\u00ae for the treatment of non-muscle invasive bladder tumors: Adverse events and predictive factors for tolerance"],"prefix":"10.1016","volume":"35","author":[{"given":"Aravind","family":"Adypagavane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Lebacle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2S","key":"10.1016\/j.fjurol.2024.102843_bib0140","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.juro.2016.10.101","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"197","author":"Morales","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102843_bib0145","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102843_bib0150","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, tT and carcinoma in situ transitional cell carcinoma of the bladder: a randomized SouthWest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102843_bib0155","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","article-title":"French AFU cancer committee guidelines\u00a0\u2013\u00a0update 2022\u20132024: non-muscle-invasive bladder cancer (NMIBC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102843_bib0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102843_bib0165","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102843_bib0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102843_bib0175","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0022-5347(01)66224-4","article-title":"The quality of life during intravesical bacillus Calmette-Guerin therapy","volume":"155","author":"Bohle","year":"1996","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102843_bib0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical Mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive Bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs. transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102843_bib0190","doi-asserted-by":"crossref","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u00a0\u2013\u00a0a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0200","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102843_bib0205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102843_bib0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0215","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Gu\u00e9rin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102843_bib0220","volume":"9","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102843_bib0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of Bacille Calmette-Gu\u00e9rin maintenance therapy for superficial Bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102843_bib0270","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13040-015-0044-6","article-title":"Mining severe drug-drug interaction adverse events using Semantic Web technologies: a case study","volume":"8","author":"Jiang","year":"2015","journal-title":"BioData Min"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0245","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.purol.2022.01.001","article-title":"Recommandations des Comit\u00e9s de canc\u00e9rologie (CC-AFU) et d\u2019infectiologie (CI-AFU) de l\u2019Association fran\u00e7aise d\u2019urologie pour la prise en charge effets ind\u00e9sirables et complications du BCG","volume":"32","author":"Audenet","year":"2022","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102843_bib0230","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-5347(17)45606-0","article-title":"Complications of Bacillus Calmette-Guerin immunotherapy in 1,278 patients with Bladder cancer","volume":"135","author":"Lamm","year":"1986","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.fjurol.2024.102843_bib0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102843_bib0240","article-title":"\u00c9valuation de la tol\u00e9rance de la BCG th\u00e9rapie endov\u00e9sicale en France\u00a0: analyse des \u00e9v\u00e8nements ind\u00e9sirables graves notifi\u00e9s sur une p\u00e9riode de trois ans","volume":"8","author":"Debois","year":"2001","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0250","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial Bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102843_bib0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","article-title":"Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Gu\u00e9rin: results from European Organisation","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102843_bib0260","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"L\u00fcftenegger","year":"1996","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102843_bib0265","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.urology.2006.03.084","article-title":"The role of the urinary epithelium in the pathogenesis of interstitial cystitis\/prostatitis\/urethritis","volume":"69","author":"Parsons","year":"2007","journal-title":"Urology"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024003115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024003115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:57:27Z","timestamp":1745233047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024003115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2950393024003115"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102843","relation":{},"ISSN":["2950-3930"],"issn-type":[{"type":"print","value":"2950-3930"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG MEDAC\u00ae for the treatment of non-muscle invasive bladder tumors: Adverse events and predictive factors for tolerance","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102843"}}